Results 41 to 50 of about 71 (52)

Bemarituzumab as First-Line Treatment for Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Final Analysis of the Randomized Phase 2 FIGHT Trial [PDF]

Gastric Cancer
BACKGROUND: We report the final results of the randomized phase 2 FIGHT trial that evaluated bemarituzumab, a humanized monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b), plus mFOLFOX6 in patients with FGFR2b-positive (2 ...
Anita Zahlten-Kumeli, Erika Hitre, Peter C Enzinger   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

FIGHT-Studie: Bemarituzumab Beim Magenkarzinom

InFo Hämatologie + Onkologie, 2021
Silke Wedekind
exaly   +2 more sources

Covariate Effects and Population Pharmacokinetic Analysis of the Anti-FGFR2b Antibody Bemarituzumab in Patients From Phase 1 to Phase 2 Trials

Cancer Chemotherapy and Pharmacology, 2021
Hong Xiang, Helen Collins
exaly  

Bemarituzumab in Patients With FGFR2b-Selected Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FIGHT): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study

Lancet Oncology, The, 2022
Erika Hitre, Peter C Enzinger
exaly  

Population Pharmacokinetic Analysis of Phase 1 Bemarituzumab Data to Support Phase 2 Gastroesophageal Adenocarcinoma FIGHT Trial

Cancer Chemotherapy and Pharmacology, 2020
Hong Xiang, Helen Collins
exaly  

Bemarituzumab With Modified Folfox6 for Advanced Fgfr2-Positive Gastroesophageal Cancer: Fight Phase Iii Study Design

Future Oncology, 2019
Daniel V T Catenacci
exaly  

Bemarituzumab Is Active in FGFR2b-High Gastroesophageal Adenocarcinoma

Cancer Discovery, 2020
exaly  

Phase I Results From the Phase 1/3 FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric/GEJ Cancer (GC).

Journal of Clinical Oncology, 2019
Hong Xiang, Daniel V T Catenacci, Aaron J Scott   +2 more
exaly  

Bemarituzumab Plus mFOLFOX6 as First-Line Treatment in East Asian Patients With FGFR2b-Overexpressing Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer: Subgroup of FIGHT Final Analysis

Gastric Cancer
Yoon-Koo Kang, Anita Zahlten-Kumeli, Zhuchen Yan   +2 more
exaly  

Ocular Safety Evaluation of Bemarituzumab in FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma: A 42-Week Follow-Up Study

Ocular Immunology and Inflammation
Fangqi Liu
exaly